Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00452387 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Stopped Early stopping rule

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: Mitoxantrone
DRUG: Prednisone
DRUG: Sorafenib

Sponsor

Accelerated Community Oncology Research Network

Collaborators

[object Object]